ScripRoche affiliate Chugai Pharmaceutical Co. Ltd. is facing the first direct biosimilar competition in Japan to what is by far its top-selling product, the anticancer Avastin. While at first sight the
ScripA lower court in Japan has dismissed an effort by originators to halt biosimilar competition to a big-selling hematological cancer drug, meaning the product will continue to face such lower-priced com
ScripJapan's Kyowa Hakko Kirin Co. Ltd. has licensed in marketing rights in its home market to a biosimilar version of the anticancer drug rituximab being developed by Novartis AG 's generics arm
ScripUS firm Anthera Pharmaceuticals Inc.'s development partner in Japan for autoimmune disorder drug blisibimod has served a termination notice for the late 2014 deal, but the US firm says the impact coul